What can we learn from Wegovy and what can manufacturers do to unlock better health for patients globally?
Published on April 9, 2023
The recent introduction of Wegovy has garnered attention from clinical and economic stakeholders alike, causing a shift in the treatment paradigm for obesity. What can manufacturers learn from Wegovy to unlock better health for patients globally? We share key learnings in our article.
Chronic weight management therapies have captured significant public attention. News channels and social media platforms are abuzz with discussions about semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), namely their long-term impact on body weight in patients with obesity, and how to secure access to these therapies.
Historically, the clinical value and need to reimburse weight management therapies has been challenged by multiple stakeholders,…
